With the United States’ thriving IPO market, low volatility and large pool of investors, many U.K. biotechnology companies have explored going public on the other side of the Atlantic.
Steep entry barriers may deter these plans before they even get off the ground, preventing firms from capitalizing on the U.S. market’s potential.
CFGI is a leading independent advisory partner with extensive experience helping companies cross the international IPO border and enter the U.S. public markets.
Download our eBook to learn how CFGI takes U.K. companies through the IPO readiness process.